Research programme: transduced autologous restorative gene therapy - Aevi Genomic Medicine

Drug Profile

Research programme: transduced autologous restorative gene therapy - Aevi Genomic Medicine

Alternative Names: Hemodure™; TARGTCNS

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medgenics
  • Developer Aevi Genomic Medicine; Harvard University; Medgenics
  • Class Gene therapies; Interferons; Proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical CNS disorders
  • Discontinued Haemophilia A

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 06 Jan 2016 Medgenics in-licenses GeneRide promoter less gene therapy technology from the Stanford University
  • 05 Feb 2013 Preclinical development in Haemophilia A is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top